- Home
- URGN vs GLRE Comparison
URGN vs GLRE Comparison
Compare URGN & GLRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- GLRE
- Stock Information
- Founded
- URGN 2004
- GLRE 2004
- Country
- URGN United States
- GLRE Cayman Islands
- Employees
- URGN N/A
- GLRE N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- GLRE Property-Casualty Insurers
- Sector
- URGN Health Care
- GLRE Finance
- Exchange
- URGN Nasdaq
- GLRE Nasdaq
- Market Cap
- URGN 547.1M
- GLRE 471.2M
- IPO Year
- URGN 2017
- GLRE 2007
- Fundamental
- Price
- URGN $12.84
- GLRE $13.97
- Analyst Decision
- URGN Strong Buy
- GLRE
- Analyst Count
- URGN 5
- GLRE 0
- Target Price
- URGN $44.50
- GLRE N/A
- AVG Volume (30 Days)
- URGN 764.9K
- GLRE 91.4K
- Earning Date
- URGN 11-12-2024
- GLRE 11-06-2024
- Dividend Yield
- URGN N/A
- GLRE N/A
- EPS Growth
- URGN N/A
- GLRE N/A
- EPS
- URGN N/A
- GLRE 1.90
- Revenue
- URGN $85,011,000.00
- GLRE $688,993,000.00
- Revenue This Year
- URGN $16.49
- GLRE N/A
- Revenue Next Year
- URGN $57.58
- GLRE N/A
- P/E Ratio
- URGN N/A
- GLRE $7.25
- Revenue Growth
- URGN 17.22
- GLRE 13.65
- 52 Week Low
- URGN $10.60
- GLRE $10.49
- 52 Week High
- URGN $20.70
- GLRE $14.31
- Technical
- Relative Strength Index (RSI)
- URGN 49.60
- GLRE 56.93
- Support Level
- URGN $11.84
- GLRE $13.64
- Resistance Level
- URGN $13.54
- GLRE $13.91
- Average True Range (ATR)
- URGN 0.82
- GLRE 0.24
- MACD
- URGN 0.08
- GLRE 0.02
- Stochastic Oscillator
- URGN 65.88
- GLRE 97.26
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About GLRE Greenlight Capital Re Ltd.
Greenlight Capital Re Ltd offers property and casualty reinsurance. Its customers are property and casualty insurers, and Greenlight takes on some of their risk in exchange for insurance premiums. It operates through one operating segment: property and casualty reinsurance. It generates revenue through premiums from reinsurance on property and casualty business assumed, and income from investments.